West Pharmaceutical: HVP growth and SmartDose sale lift Q3 results
TradingView reports West Pharmaceutical Services raised FY26 sales and EPS guidance after Q3 growth led by HVP Components and a SmartDose sale gain.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to TradingView, West Pharmaceutical Services (WST) posted a strong rise in third-quarter sales and adjusted earnings per share, with HVP Components as the main driver. On that basis, the company raised its sales and EPS guidance for fiscal 2026.
Reported profit was boosted by a gain on the sale of the SmartDose business, while adjusted operating profit also rose.
why it matters
For the market, the key point is that growth came from the core business, and the higher guidance gives investors a firmer outlook. The SmartDose gain lifted reported profit, so analysts usually focus on adjusted figures.
market impact
WST shares: strong quarter and higher guidance support the stock
- WST shares pressure up — strong quarterly results and raised 2026 guidance support investor interest in the stock
tags
instruments
sources
- WST: HVP-led growth lifted Q3 results and drove higher FY26 guidance — TradingView, 29 October 2026 at 10:07 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗